Modality
siRNA
MOA
STINGag
Target
MDM2
Pathway
Neuroinflam
AS
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
~Jul 2020
→ ~Oct 2021
Phase 3
~Jan 2022
→ ~Apr 2023
NDA/BLA
Jul 2023
→ Sep 2030
NDA/BLACurrent
NCT05292029
725 pts·AS
2023-07→2030-09·Active
725 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-234.5y awayPh3 Readout· AS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2030-09-23 · 4.5y away
AS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05292029 | NDA/BLA | AS | Active | 725 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 |